ImageneBio, Inc. Net Income
ImageneBio, Inc. (IMA) reported Net Income of -$10.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-05
- ImageneBio, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$10.18M.
- ImageneBio, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$10.62M.
- ImageneBio, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$6.91M.
- ImageneBio, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$24.78M.
- ImageneBio, Inc. net income (loss) attributable to parent for fiscal 2025 was -$45.35M.
- ImageneBio, Inc. net income (loss) attributable to parent for fiscal 2024 was -$36.57M.
- ImageneBio, Inc. net income (loss) attributable to parent for fiscal 2023 was -$68.17M.
- ImageneBio, Inc. net income (loss) attributable to parent for fiscal 2022 was -$68.77M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.18M 10-Q · filed 2026-08-05 | -$20.80M 10-Q · filed 2026-08-05 | -$27.70M derived: sum of 3 quarters · filed 2026-08-05 | -$52.48M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$10.62M 10-Q · filed 2026-08-05 | -$17.53M derived: sum of 2 quarters · filed 2026-08-05 | -$42.31M derived: sum of 3 quarters · filed 2026-08-05 | -$49.89M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$31.69M derived: sum of 2 quarters · filed 2026-03-10 | -$39.27M derived: sum of 3 quarters · filed 2026-08-05 | -$45.35M 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | -$24.78M 10-Q · filed 2025-11-12 | -$32.36M derived: sum of 2 quarters · filed 2026-08-05 | -$38.44M 10-Q · filed 2025-11-12 | -$43.25M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$7.58M 10-Q · filed 2026-08-05 | -$2.77M 10-Q · filed 2025-07-24 | -$13.66M 10-Q · filed 2026-08-05 | -$11.39M 10-Q · filed 2025-07-24 | -$18.47M derived: sum of 3 quarters · filed 2026-08-05 | -$21.66M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$6.08M 10-Q · filed 2026-08-05 | -$8.62M 10-Q · filed 2025-05-08 | -$10.89M derived: sum of 2 quarters · filed 2026-08-05 | -$14.07M derived: sum of 3 quarters · filed 2026-08-05 | -$20.33M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2024-12-31 | -$4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$8.00M derived: sum of 2 quarters · filed 2026-03-10 | -$14.25M derived: sum of 3 quarters · filed 2026-03-10 | -$36.57M 10-K · filed 2026-03-10 | -$49.23M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | -$3.18M 10-Q · filed 2025-11-12 | -$10.23M 10-Q · filed 2024-11-07 | -$9.44M derived: sum of 2 quarters · filed 2025-11-12 | -$31.76M 10-Q · filed 2025-11-12 | -$40.11M 10-Q · filed 2024-11-07 | -$51.24M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$6.26M 10-Q · filed 2025-11-12 | -$13.73M 10-Q · filed 2024-08-08 | -$29.88M 10-Q · filed 2025-07-24 | -$48.06M derived: sum of 3 quarters · filed 2025-11-12 | -$65.41M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-03-31 | -$22.31M 10-Q · filed 2025-11-12 | -$16.15M 10-Q · filed 2024-05-13 | -$41.80M derived: sum of 2 quarters · filed 2025-11-12 | -$59.15M derived: sum of 3 quarters · filed 2025-11-12 | -$76.26M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2023-12-31 | -$19.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$36.83M derived: sum of 2 quarters · filed 2025-03-06 | -$53.95M derived: sum of 3 quarters · filed 2025-03-06 | -$68.17M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$17.34M 10-Q · filed 2024-11-07 | -$34.46M derived: sum of 2 quarters · filed 2024-11-07 | -$48.68M 10-Q · filed 2024-11-07 | -$62.77M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$17.11M 10-Q · filed 2024-11-07 | -$31.33M 10-Q · filed 2024-08-08 | -$45.43M derived: sum of 3 quarters · filed 2024-11-07 | -$62.77M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-03-31 | -$14.22M 10-Q · filed 2024-11-07 | -$28.32M derived: sum of 2 quarters · filed 2024-11-07 | -$45.65M derived: sum of 3 quarters · filed 2024-11-07 | -$66.14M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2022-12-31 | -$14.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$31.43M derived: sum of 2 quarters · filed 2024-03-12 | -$51.93M derived: sum of 3 quarters · filed 2024-03-12 | -$68.77M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | -$17.34M 10-Q · filed 2023-11-09 | -$37.83M derived: sum of 2 quarters · filed 2023-11-09 | -$54.67M 10-Q · filed 2023-11-09 | -$51.87M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | -$20.49M 10-Q · filed 2023-11-09 | -$37.33M 10-Q · filed 2023-08-10 | -$34.53M derived: sum of 3 quarters · filed 2023-11-09 | -$49.05M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-03-31 | -$16.84M 10-Q · filed 2023-11-09 | -$14.04M derived: sum of 2 quarters · filed 2023-11-09 | -$28.56M derived: sum of 3 quarters · filed 2023-11-09 | -$41.24M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2021-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$11.72M derived: sum of 2 quarters · filed 2023-03-14 | -$24.40M derived: sum of 3 quarters · filed 2023-03-14 | -$34.12M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | -$14.52M 10-Q · filed 2022-11-07 | -$27.20M derived: sum of 2 quarters · filed 2022-11-07 | -$36.91M 10-Q · filed 2022-11-07 | -$62.96M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | -$12.68M 10-Q · filed 2022-11-07 | -$22.40M 10-Q · filed 2022-08-11 | -$48.45M derived: sum of 3 quarters · filed 2022-11-07 | -$54.67M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-03-31 | -$9.72M 10-Q · filed 2022-11-07 | -$35.77M derived: sum of 2 quarters · filed 2022-11-07 | -$41.99M derived: sum of 3 quarters · filed 2022-11-07 | -$47.03M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2020-12-31 | -$26.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$32.27M derived: sum of 2 quarters · filed 2022-03-17 | -$37.31M derived: sum of 3 quarters · filed 2022-03-17 | -$44.26M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | -$6.22M 10-Q · filed 2021-11-10 | -$11.26M derived: sum of 2 quarters · filed 2021-11-10 | -$18.20M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | -$5.04M 10-Q · filed 2021-11-10 | -$11.98M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$6.95M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |